155377-19-8

Basic information

• Product Name: ETHYL 3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE
• Synonyms: BUTTPARK 29\06-81;ETHYL 3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE;ETHYL 3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-4-CARBOXYLATE;3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLIC ACID, ETHYL ESTER;ETHYL 3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-4-;Ethyl 3-(trifluoromethyl)pyrazole-4-carboxylate 97%;Ethyl3-(trifluoromethyl)pyrazole-4-carboxylate97%;Ethyl 3-(trifluoromethyl)pyrazole-4-c
• CAS NO: 155377-19-8
• Molecular Formula: C₇H₇F₃N₂O₂
• Molecular Weight: 208.14
• Product Categories: Nucleotides and Nucleosides;Bases & Related Reagents;Nucleotides;Esters;Pyrazoles & Triazoles;Building Blocks;Heterocyclic Building Blocks;Pyrazoles
• Mol File: 155377-19-8.mol

Chemical Properties

• Melting Point: 145 °C
• Boiling Point: 301.3 °C at 760 mmHg
• Flash Point: 136 °C
• Appearance: /
• Density: 1.397 g/cm³
• Vapor Pressure: 0.00781mmHg at 25°C
• Refractive Index: 1.57
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: soluble in Methanol
• PKA: 8.26±0.50(Predicted)
• CAS DataBase Reference: ETHYL 3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE(155377-19-8)
• EPA Substance Registry System: ETHYL 3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE(155377-19-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 155377-19-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
ETHYL 3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows it to be a valuable building block for creating a range of molecules with diverse applications in different industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, ETHYL 3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE is used as a starting material for the development of new drugs. Its chemical properties make it suitable for the synthesis of various drug candidates, potentially leading to the discovery of novel therapeutic agents.
Used in Chemical Research:
ETHYL 3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE is also employed in chemical research as a reagent for studying the properties and reactions of pyrazole-based compounds. This helps researchers gain a deeper understanding of the structure-activity relationships and the potential applications of these compounds in various fields.
Used in Material Science:
In the field of material science, ETHYL 3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE can be used as a component in the development of new materials with specific properties. Its incorporation into polymers or other materials may lead to the creation of materials with enhanced characteristics, such as improved stability, reactivity, or selectivity.

InChI:InChI=1/C7H5F3IN/c8-7(9,10)5-3-4(12)1-2-6(5)11/h1-3H,12H2

Upstream product

• 372-31-6 ethyl 4,4,4-trifluoroacetoacetate 
• 122-51-0 orthoformic acid triethyl ester 
• 371-67-5 2,2,2-trifluorodiazoethane 
• 5941-50-4 ethyl β-nitroacrylate 
• 5941-50-4 (E)-ethyl 3-nitroacrylate 
• 16205-84-8 ethyl 3-(trimethylsilyl)propynoate 
• 1048670-08-1 2-[1-ethoxy-meth-(Z)-ylidene]-4,4,4-trifluoro-3-oxo-butyric acid ethyl ester 
• 354-34-7 trifluoroacetyl fluoride 
• 64-17-5 ethanol 
• 571-55-1 ethyl 2-(ethoxymethylidene)-4,4,4-trifluoro-3-oxobutanoate 

Downstream Products

• 850008-86-5 ethyl 1-[2-(2-bromophenyl)ethyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 741717-63-5 ethyl 1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1001020-13-8 (3-(trifluoromethyl)-1H-pyrazolyl-4-yl)methanol 
• 1004528-48-6 ethyl 1-(3-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1003579-06-3 ethyl 1-(2-hydroxyphenyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1003577-87-4 N-(2-{[(4-ethoxyphenyl)carbonyl]amino}ethyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide 
• 543739-84-0 3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid 
• 142818-01-7 1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid 
• 928053-15-0 3-trifluoromethyl-1-trityl-1H-pyrazole-4-carboxylic acid ethyl ester 
• 338959-51-6 ethyl 1-(4-cyanophenyl)-3-trifluoromethylpyrazole-4-carboxylate 
• 1199829-02-1 ethyl 1-((1-(benzyloxycarbonylamino)-2,3-dihydro-1H-inden-5-yl)methyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1199828-87-9 (S)-ethyl 1-((2-(benzyloxycarbonylamino)-2,3-dihydro-1H-inden-5-yl)methyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 958132-52-0 ethyl 1-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1003579-02-9 ethyl 1-(3-ethoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 

Relevant articles and documents

"Reported, but still unknown." A closer look into 3,4-bis- and 3,4,5-tris(trifluoromethyl)pyrazoles

Straightforward practical synthetic approaches to 3,4-bis- and 3,4,5-tris(trifluoromethyl)pyrazoles have been developed. The key step of the both syntheses is a transformation of the carboxylic group in a pyrazole core into the trifluoromethyl group by sulfur tetrafluoride. The elaborated synthetic protocols allow gram-scale preparation of the target products. The obtained compounds are comprehensively characterized by means of crystallographic analysis, determination of pKa values and fluorescence measurements.

DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Visceral leishmaniasis (VL) is a parasitic disease endemic across multiple regions of the world and is fatal if untreated. Current therapies are unsuitable, and there is an urgent need for safe, short-course, and low-cost oral treatments to combat this ne

Preparation method for polyhalogenated methylpyrazole formate

The invention discloses a preparation method for polyhalogenated methylpyrazole formate. The preparation method comprises the following specific steps: with a compound with a chemical structural formula I which is described in the specification and formyl acetate sodium salt as raw materials, subjecting the compound and the formyl acetate sodium salt to a low-temperature reaction in an organic solvent for 0.5-4 h under the action of a quaternary ammonium salt catalyst, then adding substituted hydrazine, and carrying out a cyclization reaction for 0.5-4 h so as to generate the polyhalogenated methylpyrazole formate as shown in a formula II which is described in the specification. The preparation method provided by the invention has the advantages of safe and easily-controllable process, mild synthesis condition, high atom economy, low emission of three wastes and good industrial value.

Expedient discovery for novel antifungal leads targeting succinate dehydrogenase: Pyrazole-4-formylhydrazide derivatives bearing a diphenyl ether fragment

The pyrazole-4-carboxamide scaffold containing a flexible amide chain has emerged as the molecular skeleton of highly efficient agricultural fungicides targeting succinate dehydrogenase (SDH). Based on the above vital structural features of succinate dehydrogenase inhibitors (SDHI), three types of novel pyrazole-4-formylhydrazine derivatives bearing a diphenyl ether moiety were rationally conceived under the guidance of a virtual docking comparison between bioactive molecules and SDH. Consistent with the virtual verification results of a molecular docking comparison, the in vitro antifungal bioassays indicated that the skeleton structure of title compounds should be optimized as an N′-(4-phenoxyphenyl)-1H-pyrazole-4-carbohydrazide scaffold. Strikingly, N′-(4-phenoxyphenyl)-1H-pyrazole-4-carbohydrazide derivatives 11o against Rhizoctonia solani, 11m against Fusarium graminearum, and 11g against Botrytis cinerea exhibited excellent antifungal effects, with corresponding EC50 values of 0.14, 0.27, and 0.52 μg/mL, which were obviously better than carbendazim against R. solani (0.34 μg/mL) and F. graminearum (0.57 μg/mL) as well as penthiopyrad against B. cinerea (0.83 μg/mL). The relative studies on an in vivo bioassay against R. solani, bioactive evaluation against SDH, and molecular docking were further explored to ascertain the practical value of compound 11o as a potential fungicide targeting SDH. The present work provided a non-negligible complement for the structural optimization of antifungal leads targeting SDH.

A new method for making pyrazole or pyrimidinone

The invention relates to the use of an amine compound in a method for producing a fluorinated or non-fluorinated 5- or 6-membered heterocyclic compound (preferably pyrazole or pyrimidinone) containingtwo nitrogen atoms in a ring system. The invention also relates to a method for producing a pyrazole or pyrimidinone, which may be fluorinated or may not be fluorinated (non-fluorinated). Each of thefluorinated pyrazole or fluorinated pyrimidinone is a very important structural unit for pharmaceutical and agricultural applications. For example, fungicides are strongly dependent on bifenapram, fluoxastrobin, flubenazolid, fluoxastrobin, pyraclostrobin, and pyracloprid, each with this fluorinated pyrazole as a key structural unit, and benflufenazole respectively, or diflufenacil and chlorfensulfazone (dimethachlor).

FUSED BICYCLIC COMPOUNDS

Described herein are fused bicyclic compounds, compositions, and methods for their preparation. Described herein are processes for the synthesis of FXR modulatators.

COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS

Described herein are methods of treating a metabolic disorder in an individual in need thereof, comprising co-administering to the individual a therapeutically effective amount of an FXR modulator, and at least one second agent that is an CCR2/CCR5 antagonist, ASKl inhibitor, DPP-IV inhibitor, caspase protease inhibitor, SGLT2 inhibitor, acetyl-CoA carboxylase (ACC) inhibitor, diacyl glycerol acyltransferase-1 inhibitor, sodium -bile acid cotransporter-inhibitor, TLR-4 antagonist, PPAR alpha/delta agonist, or GLP-1 agonist, or a combination thereof.

Synthesis of Celecoxib, Mavacoxib, SC-560, Fluxapyroxad, and Bixafen Enabled by Continuous Flow Reaction Modules

Multi-step continuous flow synthesis enables a parallel approach to obtain agrochemicals and pharmaceuticals containing 3-fluoroalkyl pyrazole cores. In this system, fluorinated amines are transformed into pyrazole cores through a telescoped in situ generation and consumption of diazoalkanes. Once synthesized, additional continuous flow and batch reactions add complexity to the pyrazole core via C–N arylation and methylation, TMS cleavage, and amidation. Using this modular assembly line approach, Bixafen and Fluxapyroxad were synthesized in 38 % yield over four continuous flow steps in an overall reaction time of 56 min. Finally, coupling selected continuous flow processes with an offline (batch) Ullmann coupling afforded Celecoxib, Mavacoxib, and SC-560 in 33–54 % yield over two to three steps.

Use of a Traceless Activating and Directing Group for the Construction of Trifluoromethylpyrazoles: One-Pot Transformation of Nitroolefins and Trifluorodiazoethane

We disclose an efficient one-pot transformation of trifluorodiazoethane and higher perfluorinated homologues with various nitroolefins. This method takes advantage of the nitro group as a traceless activating and directing group (TADG) that is released in the aromatization step to produce 4-substituted 3-perfluoroalkyl pyrazoles with complete regioselectivity. The potential of this method is further demonstrated by the synthesis of penthiopyrad.

Preparation method of 3-fluoroalkyl-1H-pyrazole-4-formic ester

The invention provides a preparation method of 3-fluoroalkyl-1H-pyrazole-4-formic ester. Compared with the prior art, the preparation method comprises the steps of mixing 3-nitro acrylate shown in the formula (I), a fluoroalkyl diazo compound shown in the formula (II), a catalyst, an alkali compound in an organic solvent, and reacting to obtain the 3-fluoroalkyl-1H-pyrazole-4-formic ester shown in the formula (III). The preparation method provided by the invention is simple in operating steps, mild in reaction condition, high in yield, good in universality of a substrate, and meanwhile a product has higher purity.